H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 33.15 DKK 0.61%
Market Cap: 33B DKK
Have any thoughts about
H Lundbeck A/S?
Write Note

EV/EBIT
Enterprise Value to EBIT

7.3
Current
3.6
Median
16.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
7.3
=
Enterprise Value
28.7B DKK
/
EBIT
3.9B DKK
All Countries
Close
Market Cap EV/EBIT
DK
H Lundbeck A/S
CSE:HLUN A
32.9B DKK 7.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 23.7
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 12.4
CH
Roche Holding AG
SIX:ROG
199.4B CHF 11.6
UK
AstraZeneca PLC
LSE:AZN
161.4B GBP 253.8
CH
Novartis AG
SIX:NOVN
170.9B CHF 13.1
US
Pfizer Inc
NYSE:PFE
149.4B USD 15.8
EBIT Growth EV/EBIT to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBIT: 1 810.7
7.3
-1%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23.7
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
8

See Also

Discover More